Darolutamide (Nubeqa, BAY1841788) Clinical Trials

3 actively recruiting trials across 1 location

Also known as: ODM-201

Pipeline

Phase 3: 1Phase 4: 1

Top Sponsors

Bayer3

Indications

Cancer3
Non-metastatic Castration-resistant Prostate Cancer2
Metastatic Hormone-sensitive Prostate Cancer1

Other2 trials

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Phase 4

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Homewood, Alabama1 trial

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Urology Centers of Alabama, PC

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.